Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor

Leukemia Research

Volumn 38, Issue 3, 2014, Pages 316-322

  Verstovsek, Srdan ^a   Tam, Constantine S ^a   Wadleigh, Martha ^b   Sokol, Lubomir ^c   Smith, Catherine C ^d   Bui, Lynne A ^e   Song, Chunyan ^e   Clary, Douglas O ^e   Olszynski, Patrycja ^d   Cortes, Jorge ^a   Kantarjian, Hagop ^a   Shah, Neil P ^d  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e EXELIXIS INC   (United States)

Author keywords

Inhibitor; JAK2; Mutation; Myelofibrosis; XL019

Indexed keywords

INHIBITOR; JAK2; MUTATION; MYELOFIBROSIS; XL019;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; EARLY TERMINATION OF CLINICAL TRIALS; FEMALE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; NEUROTOXICITY SYNDROMES; PRIMARY MYELOFIBROSIS; PROLINE; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 84894253077     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.12.006     Document Type: Article

References (29)

1. Tefferi A., Thiele J., Vardiman J.W. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer 2009, 115:3842-3847.
2. Mesa R.A., Silverstein M.N., Jacobsen S.J., Wollan P.C., Tefferi A. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995. American Journal of Hematology 1999, 61:10-15.
3. Tefferi A. Myelofibrosis with myeloid metaplasia. The New England Journal of Medicine 2000, 342:1255-1265.
4. Vannucchi A.M. Management of myelofibrosis. Hematology/the Education Program of the American Society of Hematology American Society of Hematology Education Program 2011, 2011:222-230.
5. James C., Ugo V., Le Couedic J.P., Staerk J., Delhommeau F., Lacout C., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434:1144-1148.
6. Harrison C., Kiladjian J.J., Al-Ali H.K., Gisslinger H., Waltzman R., Stalbovskaya V., et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. The New England Journal of Medicine 2012, 366:787-798.
7. Verstovsek S., Mesa R.A., Gotlib J., Levy R.S., Gupta V., DiPersio J.F., et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine 2012, 366:799-807.
8. Pardanani A., Gotlib J.R., Jamieson C., Cortes J.E., Talpaz M., Stone R.M., et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2011, 29:789-796.
9. Verstovsek S., Kantarjian H., Mesa R.A., Pardanani A.D., Cortes-Franco J., Thomas D.A., et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. The New England Journal of Medicine 2010, 363:1117-1127.
10. Santos F.P., Kantarjian H.M., Jain N., Manshouri T., Thomas D.A., Garcia-Manero G., et al. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood 2010, 115:1131-1136.
11. Verstovsek S., Mesa R.A., Gotlib J., Levy R.S., Gupta V., DiPersio J.F., et al. Long-term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT-I. Blood: American Society of Hematology 2012.
12. Cervantes F., Kiladjian J.-J., Niederwieser D., Sirulnik A., Stalbovskaya V., McQuity M., et al. Long-term safety, efficacy, and survival findings from Comfort-II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood: American Society of Hematology 2012, 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA.
13. Verstovsek S., Pardanani A.D., Shah N.P., Sokol L., Wadleigh M., Gilliland D.G., et al. A phase 1 study of XL019 a selective JAK2 inhibitor, in patients with primary myelofibrosis and, post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood: American Society of Hematology 2007, 170A-A. 1900M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA.
14. Shah N.P., Olszynski P., Sokol L., Verstovsek S., Hoffman R., List A.F. A phase I study of XL019, a selective JAK2 inhibitor, in patients with primary myelofibrosis, post-polycythemia vera, or post-essential thrombocythemia myelofibrosis. Blood 2008, 112:98.
15. Paquette R., Sokol L., Shah N.P., Silver R.T., List A.F., Clary D.O., et al. A phase I study of XL019, a selective JAK2 inhibitor, in patients with polycythemia vera. Blood: American Society of Hematology 2008, 971. 1900M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA.
16. Dupriez B., Morel P., Demory J.L., Lai J.L., Simon M., Plantier I., et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996, 88:1013-1018.
17. Tefferi A., Barosi G., Mesa R.A., Cervantes F., Deeg H.J., Reilly J.T., et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006, 108:1497-1503.
18. Mascarenhas J., Mughal T.I., Verstovsek S. Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib. Current Medicinal Chemistry 2012, 19:4399-4413.
19. Santos F.P., Verstovsek S. JAK2 inhibitors for myelofibrosis: why are they effective in patients with and without JAK2V617F mutation?. Anti-Cancer Agents in Medicinal Chemistry 2012, 12:1098-1109.
20. Nicolas C.S., Peineau S., Amici M., Csaba Z., Fafouri A., Javalet C., et al. The Jak/STAT pathway is involved in synaptic plasticity. Neuron 2012, 73:374-390.
21. Seymour J., Scott B., Roberts A., To B., Odenike O., Estrov Z., et al. Long-term safety and efficacy analysis of the two phase 1 studies of SB1518, a novel oral JAK2 inhibitor, in patients with advanced myeloid malignancies. 16th Congress of the European Hematology Association: Haematologica Journal Office 2013, 378.
22. Tam C.S., Verstovsek S. Investigational Janus kinase inhibitors. Expert Opinion on Investigational Drugs 2013, 22:687-699.
23. Verstovsek S., Mesa R.A., Rhoades S.K., Giles J.L., Pitou C., Jones E., et al. Phase I study of the JAK2 V617F inhibitor, LY2784544, in patients with myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). Blood: American Society of Hematology 2011, 1213-1214. 1900M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA.
24. Tam C.S., Nussenzveig R.M., Popat U., Bueso-Ramos C.E., Thomas D.A., Cortes J.A., et al. The natural history and treatment outcome of blast phase BCR-ABL-myeloproliferative neoplasms. Blood 2008, 112:1628-1637.
25. Mascarenhas J., Navada S., Malone A., Rodriguez A., Najfeld V., Hoffman R. Therapeutic options for patients with myelofibrosis in blast phase. Leukemia Research 2010, 34:1246-1249.
26. Thepot S., Itzykson R., Seegers V., Raffoux E., Quesnel B., Chait Y., et al. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). Blood 2010, 116:3735-3742.
27. Pardanani A., Laborde R.R., Lasho T.L., Finke C., Begna K., Al-Kali A., et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia 2013, 27:1322-1327.
28. Kretz A., Happold C.J., Marticke J.K., Isenmann S. Erythropoietin promotes regeneration of adult CNS neurons via Jak2/Stat3 and PI3K/AKT pathway activation. Molecular and Cellular Neurosciences 2005, 29:569-579.
29. Weng Z., Signore A.P., Gao Y., Wang S., Zhang F., Hastings T., et al. Leptin protects against 6-hydroxydopamine-induced dopaminergic cell death via mitogen-activated protein kinase signaling. The Journal of Biological Chemistry 2007, 282:34479-34491.